Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 456 results for "dr reddy"

USFDA issues alert on Dr Reddy's Hyderabad unit

Recently, USFDA had issued a Form-483 with two observations after inspecting co's unit Business Standard, 5 hours ago

307 images for dr reddy

Money Control, 2 days ago
Money Control, 20 hours ago
Money Control, 1 day ago
Money Control, 2 days ago
Money Control, 3 days ago
Money Control, 3 days ago
Money Control, 1 week ago
Money Control, 1 week ago
Money Control, 2 weeks ago
Money Control, 2 weeks ago
Money Control

Indian ADRs: Dr Reddy#39;s Lab, Infosys, Tata Motors up

Indian ADRs ended mostly higher on Friday. Wipro was up 0.08 percent and Tata Motors added 0.24 percent.
 Money Control20 hours ago Indian ADRs: HDFC Bank gains 2.6%, Dr Reddy#39;s Lab up  Money Control3 days ago Indian ADRs: Tata Motors, Dr Reddy#39;s Lab, HDFC Bank down  Money Control3 days ago Indian ADRs: Infosys gains; ICICI Bank, Tata Motors, Dr Reddy#39;s Labs slip  Money Control1 week ago
Money Control

Dr Reddy's gets 11 observations from USFDA for Hyderabad plant

Drug major Dr Reddy s Laboratories today said the US health regulator has issued 11 observations after inspecting its manufacturing plant in Hyderabad.
 DNA1 day ago Dr Reddy#39;s gets 11 observations from USFDA for Hyderabad plant  Money Control1 day ago Dr Reddy's Lab advances as USFDA completes audit of plant  Business Standard1 week ago Dr Reddys Laboratories announces successful USFDA inspection of its API Srikakulam Plant  Business Standard2 weeks ago
[x]  
Money Control

Dr Reddy#39;s Laboratories launches Ezetimibe and Simvastatin tablets in US market

Dr Reddy#39;s Laboratories has launched Ezetimibe and Simvastatin Tablets, 10mg/10mg, 10mg/20mg, 10mg/40mg, and 10mg/80mg, a therapeutic equivalent generic version of Vytorin tablets in the US market, approved by USFDA.
 Money Control2 days ago Dr. Reddy's Lab launches Ezetimibe & Simvastatin tablets in US  Myiris1 day ago Dr Reddys Laboratories launches Ezetimibe and Simvastatin Tablets  Business Standard2 days ago Hold Dr. Reddy#39;s Laboratories; target of Rs 2620: Edelweiss  Money Control2 weeks ago
Money Control

Market Live: Nifty below 9150, Sensex flat; Dr Reddy#39;s gains, Sun Pharma down

Dr Reddy#39;s Labs share price rallied more than 2 percent after the USFDA has not issued any observations for Srikakulam plant.
 Money Control1 week ago Market Live: Nifty opens below 9150, Sensex flat; Dr Reddy#39;s gains, Sun Pharma down  Money Control1 week ago Market Live: Nifty hovers around 9150; Indiabulls Real, Hindalco most active  Money Control1 week ago Market Live: Sensex sluggish; HDFC, Reliance support; Adani Group stocks up  Money Control1 week ago
Sify

BUZZ-India's Dr. Reddy's Labs rises; FDA has no observations for plant

** Shares of Dr. Reddy's Laboratories Ltd rise asmuch as 3.1 pct ** Stock top pct gainer on NSE index; biggestintra-day pct gain in two weeks ** U.S. Food and Drug Administration (FDA) completes auditof co's Srikakulam plant in southern state of Andhra ...
 Sify1 week ago Dr. Reddy's Labs rises; FDA has no observations for plant  Sify1 week ago BUZZ-India's Dr. Reddy's Labs hits 2-1/2-yr low on U.S. FDA observations  Sify1 month ago Dr. Reddy's Labs hits 2-1/2-year low on US FDA observations  Sify1 month ago
Sify

Sensex down 62 points amid cautious trades; Dr Reddy's up nearly 3%

Mumbai: The Indian stock market is down slightly after a flat start Monday morning, with investors treading cautiously on weak lead from Asian markets following North Korea's attempt to test another missile. The BSE benchmark Sensex, which declined to ...
 Sify1 week ago Markets end marginally lower as investors stay wary on corporate results  Rediff.com1 week ago Sensex up marginally amid cautious trades  Sify1 month ago Sensex recovers after falling nearly 90 points; DRL down sharply  Sify1 month ago

Dr. Reddy’s Q4 PAT seen up 6.3% to Rs 499.9 cr: ICICI Securities

Net Sales are expected to increase by 2.5 percent Q-o-Q (up 1.2 percent Y-o-Y) to Rs 3800.9 crore, according to ICICI Securities. Dr. Reddy’s to report net profit at 3800.9 crore up 1.2% quarter-on-quarter.
 Money Control1 week ago

Here’s what analysts feel about Dr Reddy’s Labs post US FDA observations

Typically, the US drug regulator conveys its concerns on manufacturing practices through Form 483. Companies that receive its observations must respond in writing with a corrective action plan and implement it quickly
 Money Control1 month ago Dr Reddy's Miryalaguda plant observations minor: Edelweiss  Money Control1 month ago Can sort out USFDA concerns on Telangana plant: Dr Reddy's  Money Control1 month ago Dr Reddy's receives 3 USFDA observations for Miryalaguda plant  Money Control2 months ago
Money Control

Dr Reddy's Labs to market US-based Integra's neurological products in India

It will distribute Integra's DuraGen Plus and Suturable DuraGen Dural Regeneration in the country BS B2B Bureau | Hyderabad March 28, 2017 Last Updated at 00:44 IST Dr Reddy's Laboratories Limited has entered into an exclusive distribution agreement Integra ...
 Business Standard1 month ago Dr Reddy's to market Integra's products in India  Business Standard1 month ago Dr Reddy#39;s to market Integra LifeSciences products in India  Money Control1 month ago Dr Reddy's to market Integra LifeSciences products in India  Business Standard1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less